NewLimit develops age-reprogramming medicines by using an AI-driven genomics platform to discover transcription factor combinations that reverse cellular aging and restore metabolic, vascular, and immune health. The company has discovered a prototype medicine that reverses cellular age in old human liver cells and has accelerated that program toward clinical development. NewLimit plans to transition its lead liver-cell program into investigator-led human trials targeted for late 2027 and to expand its computational biology teams to support pipeline growth. Financially, the company raised $435 million in a Series C led by Founders Fund with broad participation from venture firms and strategic investors. NewLimit was co-founded by Brian Armstrong and Blake Byers and is led by CEO and President Jacob Kimmel.

Total raised

$787M

Funding rounds

5

Latest round

Series C

Latest activity

Jun 2026